Another study reported that treatment of AML patients with HMA+VEN results in increased frequencies of circulating effector memory CD8+ T cells (Tem) and reduced IFN-γ production by peripheral CD8+ T cells. The gene discussed is IFNG; the disease is acute myeloid leukemia.